A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms A-PREDICT
- 16 Nov 2016 Status changed from recruiting to completed.
- 15 Nov 2016 Last checked against European Clinical Trials Database record.
- 16 Oct 2015 Accrual to date is 53% according to United Kingdom Clinical Research Network record.